Advertisement

Topics

Companies Related to "Researchers identify dual parameter approach improve prostate" [Most Relevant Company Matches] RSS

22:44 EDT 21st March 2019 | BioPortfolio

Here are the most relevant search results for "Researchers identify dual parameter approach improve prostate" found in our extensive corporate database of over 50,000 company records.

Showing "Researchers identify dual parameter approach improve prostate" Companies 1–25 of 5,400+

Relevant

Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world’s largest philanthropic source of support for accelerating the world’s most promising research for discovering better treatments and cures for prostate cancer. Founded in 1993, the PCF has raised nearly $400 million and provided funding to more than 1,500 researchers at nearly 200 institutions wor...


The Prostate Cancer Foundation

The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research focused on discovering better treatments and a cure for prostate cancer at every stage of diagnosis. Founded in 1993, the PCF has raised more than $370 million and provided funding to more than 1,500 research projects at nearly 200 instit...

Minomic International Ltd

Minomic International Ltd is an Australian immuno-oncology company specialising in therapeutics and diagnostics for prostate cancer and other cancers. Minomic has developed the in vitro diagnostic test called MiCheck® for the early detection of prostate cancer. Minomic is preparing to globally launch its first product, a novel prostate cancer blood test...


Prostate Cancer Education Council

Prostate cancer remains the second-leading cause of cancer death in American men. More than 220,000 men will be diagnosed with prostate cancer this year and it is expected that 27,000 men will die from the disease. With more annual cases of prostate cancer than that of breast cancer among women, screening is imperative to ensure the health of the men of our nation.

Castleman Disease Collaborative Network (CDCN)

CDCN is a global initiative dedicated to accelerating research and treatment for Castleman disease (CD) to improve survival for all patients with CD. The CDCN’s innovative approach first involved building a global community of over 400 physicians and researchers, assembling a scientific advisory board of 28 experts from eight countries, and supporting...

Stratify Genomics, Inc.

Currently, there are 35,000 men annually who are unaware of a curable form of clinically significant prostate cancer. Relying solely on family history, 80% of prostate cancer cases would be missed. The most common screening tool, prostate-specific antigen (PSA) testing, has declined in usage due to controversial guidelines, which has led to a significant i...

Precision Biopsy, LLC

Precision Biopsy, LLC is a privately-held startup company formed by Allied Minds, Inc. in cooperation with the University of Colorado to commercialize a revolutionary optical biopsy technology designed to improve the accuracy and reliability of prostate biopsies and the diagnosis of prostate cancer. www.precisionbiopsy.com

Prostate Oncology Specialists,Inc.

Prostate Oncology Specialists is a medical group exclusively devoted to caring for men with prostate cancer. We have vast experience diagnosing and treating prostate cancer because 100% of our time is focused on managing men with this disease. Our physicians are board certified in both medical oncology and internal medicine and have made significant contributions to the scientific advancement in t...

ProUroCare Medical

Proprietary vision technologies advancing the safety and efficacy of medical diagnostics and therapeutics. ProUroCare Medical Inc. is an early-stage company that is developing innovative sensing and vision technologies to increase the safety and efficacy of medical diagnostics and therapeutic procedures. Currently, we are focused on products and technologies that use minimally invasive techniqu...

Prostate Oncology Specialists, Inc.

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 217,730 new cases and approximately 32,050 men expected to die from the disease in 2010.

Mitomics

Mitomics is the world leader in the research and development of mitochondrial DNA (mtDNA)-based biomarkers – a new and innovative approach to the detection of cancer and other disease states. Leveraging its unparalleled insights into the role of mitochondria in cancer, the company is developing an extensive and proprietary portfolio of molecular tests...

Seattle Prostate Institute

The Seattle Prostate Institute was established in 1997 by a group of physicians who, in the mid-1980's, had pioneered the introduction and development of ultrasound-guided prostate implantation in the United States from their base at Seattle's Northwest Hospital. After relocating to Swedish Medical Center, another of the city's premier institutions, these physicians sought to expand and improve up...

Cancer Vaccines Ltd

Cancer Vaccines Ltd is a biopharmaceutical company focused on the development and commercialisation of safe and effective therapeutic vaccines for the treatment of cancer. The company was founded in 1999 and won a DTI SMART Award.The attraction of a vaccination based approach to treating cancer is widely acknowledged, and many researchers and clinicians have worked in this area. Historically the a...

T1D Exchange

T1D Exchange was founded on the belief that people affected by type 1 diabetes need better solutions faster – better treatments and better care. Our nonprofit organization takes an innovative approach that puts the community of people touched by type 1 diabetes at the center of research that will meaningfully impact their lives. Our integrated model ...

ImmunSYS, Inc.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with late-stage metastatic prostate cancer and other adenocarcinomas. The company’s platform technology, YourVaccx™ utilizes a novel combination of the proprietary ANTIGENerator™ energ...

HIFU Prostate Services, LLC

At HIFU Prostate Services (HPS), our mission is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS was founded in 2015 by a seasoned management team with over 50 years of exper...

Novacea

We are a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. We currently have two clinical-stage oncology product candidates. Our lead product candidate, Asentar™ (DN-101), is in a Phase 3 clinical trial for the treatment of androgen-independent prostate cancer, or AIPC, also known as hormone-refractory prostate cancer. ...

Avalon Pharmaceuticals

Avalon Pharmaceuticals' primary mission is to discover and develop innovative small molecule therapeutics using cutting-edge genomic technologies. Through its comprehensive genomics approach, Avalon is able to pinpoint proprietary drug activity markers and drug targets and to use these for drug screening in complex biological systems, facilitating the identification of lead drug candidates. Avalon...

RC Cancer Centers

Each year thousands of patients from around the world and across the United States turn to RC Cancer Centers seeking a cure for their prostate cancer and learn why they are The Choice for Saving Lives. Founded in 1979, Radiotherapy Centers of Georgia, a division of RC Cancer Centers, has earned a reputation for being one of the country's top cancer treatment and research facilities because of its ...

Nucletron B.V.

Nucletron is a radiotherapy company that specializes in the development, manufacture, sales, service and support of the world's most innovative products for cancer treatment. As a company, our guiding principle is the customer's demand for quality, safety and reliability. We continuously invest in innovative research and development. This approach has made it possible to successfully treat cancers...

Aragon Pharmaceuticals Inc.

Aragon Pharmaceuticals is a privately held small-molecule drug discovery company identifying breakthrough medicines for the treatment of hormonally driven cancers. These cancers are traditionally treated with anti-hormonal therapies but often become resistant, and follow-on therapies are largely ineffective. The company plans to initiate a clinical trial with its lead compound, ARN-509, in patient...

Coalition to Cure Prostate Cancer

The Coalition to Cure Prostate Cancer is a philanthropic organization that funds and accelerates advanced prostate cancer research in Canada. Beginning in 2011, the Coalition has identified unique strategies to invest in the most promising research programs that generate life-saving results. By channeling resources to Canada’s top scientific minds, red ...

Tokai Pharmaceuticals

Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company’s lead drug candidate, TOK-001, is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined in one oncotherapeutic....

RxAnte, Inc.

RxAnte, Inc. is dedicated to getting more from medicines. A trusted provider of advanced analytics and targeted clinical programs for health plans and servicing more than 8 million lives, The RxAnte® systems, which are HITRUST and SOC 2-certified, identify members at risk for drug therapy problems and support delivery of appropriate clinical interventio...

Concordia Care, Inc.

Concordia Care, Inc. (Concordia) is a specialty risk transfer, care-coordination company servicing insurers, government entities, self-insured plan sponsors and other managed care organizations. Through its Pathways 2 Recovery care model, Concordia aims to improve patient-centered outcomes and reduce overall cost of quality care by applying best pra...


More From BioPortfolio on "Researchers identify dual parameter approach improve prostate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks